D. Gludovacz

发表

Tc-p829 99m of a Novel Tumor Tracer, Binding in Vivo Somatostatin Receptor Subtype Specificity and Updated Version Citing Articles E-mail Alerts Somatostatin Receptor Subtype Specificity and in Vivo Binding of a Novel Tumor Tracer, 99mtc-p8291

P. Valent, I. Virgolini, S. Lastoria, 2013 .

DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy1.

P. Angelberger, I. Virgolini, P. Smith-Jones, 1999, Endocrinology.

Variations in phosphorus acquisition from sparingly soluble forms by maize and soybean in low- and medium-P soils using P-32

J. Adu-Gyamfi, D. Gludovacz, M. Aigner, 2009 .

A 15N stable isotope semen label to detect mating in the malaria mosquito Anopheles arabiensis Patton

B. Knols, M. Helinski, L. Mayr, 2008, Parasites & Vectors.

Successful therapy of the prostaglandin defect "Wien-Hietzing" (lack of platelet high-affinity binding sites for prostaglandin I2).

H. Sinzinger, J. Kaliman, D. Gludovacz, 1990, Prostaglandins.

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.

P. Angelberger, I. Virgolini, P. Smith-Jones, 1999, Endocrinology.

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.

P. Angelberger, A. Kofler, T. Traub, 1999, Endocrinology.

Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.

T. Pangerl, M. Leimer, D. Gludovacz, 1998, Cancer research.